Immune Effectiveness of COVID-19 Vaccines

Dear Colleagues,

The COVID-19 pandemic has created a global health crisis, with devastating consequences for human lives and economies worldwide. The rapid development of vaccines against COVID-19 has been a crucial step in mitigating the impact of the pandemic.

Understanding the immune response to COVID-19 vaccines is crucial to ensure their effectiveness in preventing infection and reducing the spread of the virus, particularly in light of emerging SARS-CoV-2 variants of concern. The knowledge of the immune response to the developed and under-developed vaccines can help to improve vaccine formulation in the future, as well as guide the most effective vaccination programs. This research area has significant implications for public health policy, including vaccine distribution and vaccine hesitancy.

This Special Issue article series provides a comprehensive overview of the current state of knowledge on the immune response to COVID-19 vaccines. The articles cover topics such as vaccine efficacy and safety, immune responses in specific populations, and the potential impact of emerging viral variants on vaccine effectiveness. By gathering the latest research in this area, this series aims to provide a valuable resource for scientists, clinicians, and policymakers in the ongoing fight against the COVID-19 pandemic.

We are pleased to invite you to submit your research to this Special Issue. Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

• The immune response to novel COVID-19 under development.
• Populational studies covering the immune response to COVID-19 vaccines.
• Long-term immune response to COVID-19 vaccination.
• Relation between immune response and COVID-19 vaccine effectiveness.
• Breakthrough infections in the COVID-19 vaccinated population.
• Study of cases covering COVID-19 immune response to vaccination and infection.

I look forward to receiving your contributions.

Prof. Dr. Luciano Fernandes Huergo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.